Friday, March 31, 2023
Moderna and the Government of the Republic of Kenya have finalised an agreement to establish an mRNA manufacturing facility in the Republic of Kenya. This will be the Company's first mRNA manufacturing facility in Africa.
In partnership with the Government of the Republic of Kenya, Moderna will build a state-of-the-art mRNA facility in Kenya to produce up to 500 million doses of vaccines each year. The Company expects the new facility to enable drug substance and drug product manufacturing for Kenya and the African continent. In addition, this facility will have surge capacity to rapidly scale and respond to public health emergencies on the continent and around the world.
The finalisation of the agreement with the Government of the Republic of Kenya represents a key pillar for global public health strategy, to bring mRNA innovation to the people of Africa in areas of high unmet need, such as acute respiratory infections, as well as persistent infectious diseases like HIV and outbreak threats such as Zika and Ebola.
With this agreement, Moderna is committed to establish mRNA manufacturing facilities in Kenya, the United States, Canada, Australia, and the United Kingdom, furthering health security around the world.
